Letter from the CEO: Great progress in 2020 - we are ready for 2021!
Dear shareholder in Scandion Oncology, dear subscriber to Scandion Oncology News, At the cusp of the year 2020, and with almost 90 days for me as CEO, we can look back on a year in which Scandion Oncology entered two programs in clinical development with our lead candidate SCO-101 and we have thereby established the cornerstones in the strategic direction to become The Cancer Drug Resistance Company or said in other words: the company developing the first drugs that can revert resistance towards chemotherapy.As you are aware, this week, Scandion Oncology announced the results of the